SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
BeOne Medicines Ltd. (ONC) trades at a trailing P/E of 177.5, forward P/E of 50.9. Trailing earnings yield is 0.56%, forward earnings yield 1.96%. PEG 1.51. Graham Number is $3.70.
Criteria proven by this page:
- VALUE (31/100, Fail) — trailing P/E is well above the S&P 500 average of ~25, suggesting a premium valuation (P/E 177.5); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY 0.56%).
- Forward P/E 50.9 (down from trailing 177.5) — analysts expect earnings to grow, which would improve the valuation.
- PEG Ratio 1.51 — between 1.0–2.0 indicates moderate valuation relative to growth.
- Trailing Earnings Yield 0.56% — below bond yields — investors are paying a premium for expected growth rather than current earnings. Forward yield improves to 1.96% as earnings recover.
- Analyst consensus target $409.67 (+32.2% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 66/100 with 4/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
31/100
Price-to-Earnings & upside
Proven by this page
✓
HEALTH
83/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — ONC
Valuation Multiples
P/E (TTM)177.5
Forward P/E50.9
PEG Ratio1.51
Forward PEG1.51
P/B Ratio11.73
P/S Ratio6.92
EV/EBITDA62.4
Per Share Data
EPS (TTM)$0.20
Forward EPS (Est.)$6.09
Book Value / Share$3.05
Revenue / Share$3.73
FCF / Share$0.60
Yields & Fair Value
Earnings Yield0.56%
Forward Earnings Yield1.96%
Dividend Yield0.00%
Graham Number$3.70
SharesGrow IV$63.14 (-79.6%)
Analyst Target$409.67 (+32.2%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2016 |
-7.9 |
-0.07 |
2.67 |
880.94 |
- |
| 2017 |
-45.2 |
1.04 |
6.16 |
17.67 |
- |
| 2018 |
-11.5 |
-0.03 |
4.43 |
39.23 |
- |
| 2019 |
-10.5 |
-0.34 |
10.35 |
23.25 |
- |
| 2020 |
-13.3 |
-0.65 |
5.57 |
69.83 |
- |
| 2021 |
-17.2 |
0.84 |
4.10 |
21.37 |
- |
| 2022 |
-11.3 |
-0.41 |
5.17 |
16.02 |
- |
| 2023 |
-21.0 |
0.37 |
5.22 |
7.51 |
- |
| 2024 |
-30.2 |
1.09 |
5.84 |
5.10 |
- |
| 2025 |
115.5 |
-0.18 |
7.60 |
6.20 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$-3.90 |
$1.07M |
$-119.22M |
-11141.8% |
| 2017 |
$-2.21 |
$238.39M |
$-93.11M |
-39.1% |
| 2018 |
$-12.09 |
$198.22M |
$-673.77M |
-339.9% |
| 2019 |
$-15.86 |
$428.21M |
$-950.58M |
-222% |
| 2020 |
$-19.11 |
$308.87M |
$-1.6B |
-518.2% |
| 2021 |
$-15.21 |
$1.18B |
$-1.41B |
-120.2% |
| 2022 |
$-19.37 |
$1.42B |
$-2B |
-141.5% |
| 2023 |
$-8.45 |
$2.46B |
$-881.71M |
-35.9% |
| 2024 |
$-6.12 |
$3.81B |
$-644.79M |
-16.9% |
| 2025 |
$32.89 |
$5.34B |
$286.93M |
5.4% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$6.08 |
$5.17 – $6.77 |
$6.4B |
$6.37B – $6.48B |
11 |
| 2027 |
$9.55 |
$6.04 – $12.97 |
$7.42B |
$7.19B – $7.73B |
12 |
| 2028 |
$12.93 |
$8.18 – $18.18 |
$8.34B |
$8.27B – $8.41B |
10 |
| 2029 |
$16.17 |
$15.37 – $17.26 |
$9.27B |
$8.92B – $9.75B |
4 |
| 2030 |
$19.49 |
$18.53 – $20.80 |
$10.41B |
$10.01B – $10.95B |
4 |
